PAHO / WHO: Although new vaccines are more costly than traditional ones, they are overwhelmingly cost-effective and should continue to be considered a public health "best buy." See more here.
This resource collaborative is housed at the Harvard T.H. Chan School of Public Health, and jointly managed by the following projects: EPIC (Harvard), VoVRN (Harvard), ICAN (Thinkwell), TVEE (Johns Hopkins), DOVE (Johns Hopkins), and IMFIN (R4D). This work is made possible with funding from the Bill & Melinda Gates Foundation.